Treatment of Uncomplicated Childhood Malaria in Tanzania by Artemether+Lumefantrine – Efficacy and Genotyping

Overview

The purpose of this explorative clinical trial is to study parasite population dynamics, diversity and clearance kinetics of Plasmodium falciparum as well as determination of the molecular mechanisms associated with drug resistance during the early phase of artemether-lumefantrine treatment when the drug intake is either accompanied with or without intake of fatty food. The hypothesis is that intake of fatty food together with artemether-lumefantrine will enhance parasite clearance and thereby decrease the risk of early selection of genetic markers related to drug resistance. The study population is children aged 1-10 years with uncomplicated malaria in Bagamoyo District, Tanzania. Enrolled children will be randomly allocated to either intake of a fatty meal or not together with the study drug. Artemether-lumefantrine will be given twice daily for 3 days in standard doses according to bodyweight. Study participants will be admitted during the study period (3 days)to allow close supervision and detailed blood sampling.

Full Title of Study: “Treatment of Uncomplicated Childhood Malaria by an Artemisinin Derivative in Combination With Lumefantrine. Efficacy, Safety and Genotyping.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)

Interventions

  • Drug: artemether-lumefantrine
    • All treatment doses given either accompanied or not-accompanied with intake of fatty food.

Arms, Groups and Cohorts

  • Experimental: 1
    • All treatment doses accompanied with intake of fatty food
  • Active Comparator: 2
    • All treatment doses not-accompanied with intake of fatty food.

Clinical Trial Outcome Measures

Primary Measures

  • Number of P.falciparum genotypes identified at baseline compared with accumulated number of genotypes in all blood samples
    • Time Frame: 72 hours

Secondary Measures

  • Clearance kinetics of P. falciparum measured with PCR genotyping compared with blood slide reading
    • Time Frame: 72 hours

Participating in This Clinical Trial

Inclusion Criteria

  • Age 1-10 years – Presence of asexual P. falciparum parasitaemia of 2000-200 000/μL – No general danger signs or severe malaria present – Haemoglobin ≥70 g/L – History of fever within 24 hours OR axillary temperature ≥ 37.5Cº – No other cause of fever is detectable – No severe malnutrition – Guardian/patient has understood the procedures of the study and willing to participate Exclusion Criteria:

  • Not able to drink or breastfeed – Vomiting everything – Recent history of convulsions – Lethargic or unconscious – Unable to sit or stand (as appropriate for age) – History of allergy to test drugs – History of intake of any drugs other than paracetamol and aspirin within 3 days – Symptoms/signs of severe malaria

Gender Eligibility: All

Minimum Age: 1 Year

Maximum Age: 10 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Karolinska University Hospital
  • Collaborator
    • Muhimbili University of Health and Allied Sciences
  • Overall Official(s)
    • Anders Bjorkman, Professor, Study Director, Karolinska University Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.